This review discusses the development of selective progestin receptor modulators (SPRMs) for use in women's health and specifically the use of ulipristal acetate (UPA) as emergency contraception (EC) and as a treatment for symptomatic fibroids in women who want to preserve their fertility or avoid a hysterectomy. As an EC, UPA 30 mg should be recommended for women, within 102 h of unprotected intercourse. As a treatment of fibroids, UPA (5 mg daily dose) should be administered for periods of three months as a pre-surgical strategy, reducing bleeding and fibroid size and facilitating surgery. A proportion of these patients may even avoid surgery. Future developments will demonstrate whether UPA can be used for other indications such as endometriosis and breast cancer prevention or treatment.
INTRODUCTION
The earliest publications in Pubmed about ulipristal acetate (UPA: then known as 'CDB 2914') date from 1995. Originally termed a 'progestin antagonist', UPA is now considered to be a selective progestogen receptor modulator (SPRM). Its inclusion in Pubmed as a MESH term occurred only in 2014. A Pubmed search of the term 'ulipristal acetate' reveals only 318 hits compared with 26 679 hits for the term 'SERM' (selective estrogen receptor modulator).
SPRM is a new class of medication which might considerably influence women's health. UPA is currently used in only two instances: as emergency contraception and as a medical treatment of fibroids.
1-3 Past and current research has also been conducted for other indications, such as daily contraceptive use, treatment of adenomyosis, endometriosis, and even for breast cancer treatment. [4] [5] [6] In this article we will focus on the existing indications for UPA, 1-3 including mechanisms of actions, clinical data, side effects and safety, and also how the development of UPA might change the management of women's health.
HISTORY AND MECHANISMS OF ACTION

UPA and emergency contraception
UPA was previously known as 'the anti-progestin CDB 2914' and was the subject of studies comparable to those regarding the anti-progestin RU 486 or mifepristone. Mifepristone was the first reported anti-progestin. 7 It was the mifepristone researchers who first proposed the concept of a 'progesterone receptor modulator'. 7 Mifepristone is used for medical abortions, but was also studied as a potential contraceptive, a treatment of fibroids and endometriosis and as an anti-glucocorticoid drug. 8 Similarly, in the 1990s, CDB-2914 was studied for its antiovulatory and postcoital antifertility properties in both animals and humans.
9,10
Nowadays, SPRMs are considered progesterone receptor ligands exerting a multitude of unique tissue-selective in vivo effects.
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SPRMs act as either agonists, antagonists, or combined agonist/ antagonists, depending upon the progesterone-sensitive tissue affected by the SPRM. There are a few SPRMs besides mifepristone and UPA that have been or are currently being investigated in clinical trials. Asoprisnil has been tested for treatment of fibroids and menorrhagia, endometriosis and, in conjunction with oestrogen, for post-menopausal therapy. 12 Telapristone acetate has been investigated for fibroids, endometriosis, breast cancer, the treatment of amenorrhea and renal impairment. 13 In this article we will focus on UPA and its use as emergency contraception or as a medical treatment of fibroids.
Clinical data: UPA as emergency contraception (EC)
Available emergency contraception methods include the highdose, combined oestrogen and progestin pill, the insertion of a copper intrauterine device (IUD), the use of levonorgestrel (LNG) at a dose of 1.5 mg, and more recently the administration of oral UPA originally at the dose of 50 mg but now 30 mg.
The most effective method of EC remains the copper IUD. 14 It has the added advantage of providing future contraception, 14 is efficacious and cost-effective and can be inserted up to seven days after unprotected intercourse 14 even in a nulliparous woman. 15 However, it does have side effects as it may increase menstrual blood loss and dysmenorrhoea and must be inserted by a professional. It is contraindicated in women at increased risk of pelvic infection. Among oral hormonal solutions, UPA is more effective than the LNG method or the combined oral contraceptive 14 (Table 1) . 2, 14, 16 The mechanism of action of UPA is to delay ovulation. UPA prevents ovulation even as luteinising hormone levels are rising. Consideration should be given to delaying the start of POP for at least five days after UPA intake in order to preserve the ovulationdelaying effects of the latter. Consistent use of condoms should be the rule during these five days.
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Experimental use of UPA as a contraception (possible future development)
Huang et al. 23 attempted to determine whether a 3-month contraceptive vaginal ring (CVR) delivering UPA can inhibit ovulation in 90% of cycles. Fifty-five healthy women with normal ovulation at baseline were randomised to receive either a low-dose (1500 μg/day) or a high-dose (2500 μg/day) UPA-CVR for two consecutive 12-week treat- 
Safety issues with UPA as EC
Post-marketing pharmacovigilance data reported that pregnancies occurred in 6.8% of patients using UPA as an EC. 24 When data from both clinical trials and from post-marketing was included a total of 376 pregnancies were reported. of the cases (vs 18.9% of those using levonorgestrel), and in 6.4%
of the post-marketing study population. In the post-marketing study, nausea, abdominal pain and vomiting were the most common symptoms occurring in 13.3% of the patients. 24 Women were advised to use a barrier method of contraception until their next period and were told that during the next menstrual cycle intermittent bleeding could occur. 24 UPA is metabolised via cytochrome P450 3A4, and thus a reduction of efficacy may occur when drugs known to induce cytochrome induction, are used.
These include rifampicin, dabrafenib, enzalutamide, certain antiepileptic drugs such as primidone, phenytoin or carbamazepine and St John's wort. 25 Whether women who breast feed should use UPA is controversial as it may be excreted in their milk.
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UPA and fibroid treatment
Treatment of fibroids has recently been reviewed. The authors proposed that these data should motivate the development of the SPRM as a long-term medical therapy for heavy menstrual bleeding. 32 Finally, PEAC changes may also occur anecdotally in ectopic endometrium. PBAC, pictorial blood-loss assessment chart, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding. Anaemia: haemoglobin level of ≤10.2 g/dL. IM LA: once/month intramuscular injection of leuprolide acetate at a dose of 3.75 mg. Amenorrhea: was classified as no more than one day of spotting in a 35-day period. †Women with at least one fibroid >3 cm and none >10 cm, HMB, (bleeding score >100 on PBAC), anaemia and uterus <16 weeks eligible for surgery.
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‡A statistically significant difference was detected between the two treatment groups at the end of course 1 but not at the end of treatment courses 2, 3 and 4.
UPA (in contrast to GnRH agonists) does not lower oestradiol levels, but does inhibit ovulation. The main results of RCTs (PEARL I-IV) assessing UPA are presented in Table 2 . 29 In PEARL I, UPA at doses of 5 or 10 mg compared with a placebo over a 13 weeks period, was effective in reducing menstrual blood loss in over 90%
of patients and resulted in amenorrhea within 10 days for threequarters of them. 29 The resulting fibroid shrinkage was maintained after discontinuation of the UPA treatment. UPA use was associated with benign endometrial changes in up to two-thirds of women during treatment. In PEARL II, UPA was compared to a GnRH analogue. 30 While there was no difference in the control of bleeding, UPA was better tolerated and more rapidly led to amenorrhea than did the GnRH analogue. 30 The UPA treated group had no rebound fibroid growth after cessation of therapy. In PEARL III, 209 symptomatic women received UPA 10 mg/day for up to four three-month periods. 34 These three-month courses of treatment were each immediately followed by a 10-day double-blind period of treatment with either norethisterone acetate (NETA) (10 mg daily) or a placebo. 34 The use of NETA between courses of UPA had no effect on PEAC. 34 After the first UPA course, amenorrhea occurred in almost 80% of the women and median fibroid volume decreased. Even more pronounced changes occurred in the following months. 34 In PEARL IV, 451 patients were treated for four recurrent 12-week courses, with a daily dose of 5 or 10 mg UPA resulting in similar bleeding control, fibroid volume reduction and reassuring safety results. 35 A systematic review and meta-analysis of UPA as short-term therapy for symptomatic fibroids 36 included the RCTs mentioned earlier. Although they observed an improved quality of life and the reduction of fibroid size using UPA, they were unable to quantify a summarised improvement for most outcomes with the exception of amenorrhea, due to the heterogeneity of available data.
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Other results 
Side effects SAE
From clinical trials to clinical practice
The development of SPRMs such as UPA has changed our current approach to symptomatic fibroids in pre-menopausal women.
3,37-39
In a retrospective analysis, Ferrero et al. 37 Zakiyah et al. 42 assessed the pharmaco-economic profile of UPA compared to leuprolide (GnRH agonist), for the pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age. Their analysis showed UPA to be economical and to have the potential to provide substantial savings for the healthcare budget in The Netherlands.
42
Future developments
Seitz et al. 43 are conducting a RCT comparing another SPRM, vilaprisan (2 mg daily), to UPA and placebo. The primary measure of efficacy will be the amenorrhoea rate; secondary measures include the time to normalised menstrual bleeding and the percentage of change in uterine fibroid volume. Endometrial changes will be monitored throughout the study. In mouse xenograft models, bearing a BRCA1 mutation, UPA was capable of reversing aberrant progesterone-induced proliferation, suggesting a potential role for UPA as a preventive breast cancer strategy.
5
Other groups also reported anti-tumorogenic effects of telapristone acetate (TPA) and UPA in mouse and rat models, or of UPA and APR19, a new selective and passive progestin receptor antagonist, supporting the potential role of these drugs in breast cancer therapy. 
